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Reply to response to Wheatley et al., Surgical excision margins in primary cutaneous 
melanoma: A meta-analysis and Bayesian probability evaluation”  Cancer Treatment 
Reviews April 2016;45:76  
 
We thank Madu et al1 for their comments regarding our systematic review.2 Their letter 
shows a serious lack of understanding of statistical methodology, especially in relation to 
meta-analysis. The expectation in a randomised trial is that the groups will be balanced 
because of the randomisation process; however, there is the possibility that, by chance, the 
groups could be imbalanced. This would not be a systematic error – i.e. a bias – but a random 
error. Meta-analysis of all the trials increases patient numbers and makes such a chance 
imbalance less likely. The supposition by Madu et al. that our results are due to chance 
differences between the arms in patient characteristics such as ulceration or  sentinel lymph 
node biopsy (SLNB) positivity is entirely speculative. They provide no evidence for such an 
assertion. In fact the presence or absence of ulceration was recorded in 4 of the 6 trials and, as 
expected, the balance was remarkably similar between the narrow and wide margin arms (see 
Table 1 ). The validity and quality of these 6 randomised studies have until now been widely 
accepted by the melanoma surgical community precisely because prognostic characteristics 
have been well-matched. Since these same prognostic variables drive the population risk of 
SLNB positivity, there is no reason to believe that differences in SLNB positivity explain our 
findings. Moreover, if there were chance imbalances, they would be just as likely to go in the 
opposite direction, in which case the adverse impact of narrow surgical margins would have 
been underestimated. As we discuss in our paper, the misinterpretation of p-values is a major 
reason for the belief that narrow margins are not inferior to wider ones (a non-significant 
difference does not mean that there is no difference); Madu et al. fall into the same trap, 
whereas in fact the effects on MSS, OS and RFS are in no way inconsistent with each other 
despite only the first being conventionally significant.   
 
Our data clearly show that increasing size of the surgical margin used to treat primary 
melanoma is associated with reduced risk of death from melanoma. As Madu et al point out, 
the real question is how our findings might be used. Firstly, the data are clinically relevant. 
They indicate that we cannot be certain that margin size has no effect on survival, and 
patients should be aware of this so that they can make decisions about treatment best suited to 
their preferences. 'Adhering to existing guidelines' should not preclude patient choice, and 
neither should the prior beliefs of the surgical community. Secondly, these findings should 
inform trial design, since otherwise an effect of margin size on melanoma survival, and the 
threshold for this, may well be missed. We agree that such trials should include stratification 
for all accepted relevant staging criteria, and this might include sentinel lymph node biopsy. 
 
From Wheatley K, Wilson JS, Gaunt P and Marsden JR.  June 2016 
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Table 1.  Study Characteristics – detailed table.    
 
 
Trial name  Trial details Number in trial Population general characteristics 
 
 
Melanoma characteristics 
 
 
Surgical characteristics 
Margin width 
Deviations  
 Date of trial 
recruitment 
Median follow 
up 
Country 
Narrow 
 
Wide Narrow 
 
Age: median 
(range) 
Gender: m/f % 
Wide 
 
Age: median 
(range) 
Gender: m/f % 
Narrow 
 
Melanoma size (mm) 
Location 
Ulceration: 
Wide 
 
Melanoma size (mm) 
Location 
Ulceration: 
 
Narrow 
 
Margin width (cm) 
Deviations 
Wide 
 
Margin width (cm) 
Deviations 
WHO 
melanoma 
Trial  
 
[Cascinelli 
N et al. 
1998 3 
Veronesi U 
et al. 19912 
Veronesi U 
et al. 19881] 
 
  Inclusion criteria: Histologically 
confirmed stage I melanoma 
Inclusion criteria: 2mm or less thick.  Planned width: narrow = 1cm, wide = 3cm 
Extending to muscular facia. Margins 
measured by surgeon.  
1980 to 1985 
 
Follow up data 
available for 12 
yrs. Mean 
duration 91mths 
n = 305 n = 307 Age yrs: n (%) 
 0-20: 6pts (2) 
21-40 101 pts 
(46.5) 
41-50: 84 
pts(52.8) 
51-65: 
114pts(49.6) 
Age yrs:  
 0-20: 0 
21- 40: 116 pts 
(53.5) 
41-50: 75pts 
(47.2) 
51-65; 116 pts 
(50.4) 
Median: 0.99 
Range: SD 0.53 
Distribution n (%) 
0 - 0.5: 62 (20) 
0.51 – 1.0: 123 (40) 
1.1 – 1.5 : 65 (21) 
1.51 – 2.0: 48 (16) 
≥ 2.1: 5 (2) 
Unknown: 2 (1)  
 
Location n (%) 
Arm:60pts (49.6) 
Leg:124pts (49.4) 
Trunk: 121pts (50.4) 
 
Clark level of 
invasion: pts (%) 
I: 11 (4) 
II: 109 (36) 
III: 119 (39) 
IV:37 (12) 
V:0 
Unknown: 29 (9) 
Median: 1.02  
Range: SD 0.49 
Distribution n (%) 
0 - 0.5: 50 (16) 
0.51 – 1.0: 121 (39) 
1.1 – 1.5: 83 (27) 
1.51 – 2.0: 49 (16) 
≥ 2.1: 4 (1) 
Unknown: 0 
 
Location n (%) 
Arm:61pts (50.4) 
Leg: 127pts (50.6) 
Trunk: 119pts (49.6) 
 
Clark level of 
invasion: pts (%) 
I: 6 (2) 
II: 98 (32) 
III: 136 (44) 
IV: 44(14) 
V: 0 
Unknown: 23 (8 ) 
1cm 3cm 
  
Trial name  Trial details Number in trial Population general characteristics 
 
 
Melanoma characteristics 
 
 
Surgical characteristics 
Margin width 
Deviations  
 Date of trial 
recruitment 
Median follow 
up 
Country 
Narrow 
 
Wide Narrow 
 
Age: median 
(range) 
Gender: m/f % 
Wide 
 
Age: median 
(range) 
Gender: m/f % 
Narrow 
 
Melanoma size (mm) 
Location 
Ulceration: 
Wide 
 
Melanoma size (mm) 
Location 
Ulceration: 
 
Narrow 
 
Margin width (cm) 
Deviations 
Wide 
 
Margin width (cm) 
Deviations 
 
 
 
 
 
Swedish I 
MSG Trial 
 Swedish 
 
Cohn-
Cedermark 
G et al. 
20005 
Ringborg U 
et al. 19964 
  Inclusion criteria: Histologically 
proven curtaneous, malignant 
melanoma.  
Inclusion criteria: >0.8mm to ≤2.0mm on trunk 
or extremity excluding hands &  feet. 
Planned width: narrow = 2cm, wide = 5cm 
Excision down to the muscular facia.. 
Surgery within 6 weeks of primary 
diagnostic procedure.  
1982 – 1990 
 
Median follow 
up: 132mths 
(11yrs) 
Range: 7 – 17 
yrs 
 
Sweden 
476 513 Age: 52 (16-81) 
Gender: 47/53% 
Age: 51 (16-84) 
Gender: 48/52 
Median: 1.2 
Range: 0.4 – 2.9 
Distribution % 
ns 
 
Location n (%) 
Head – neck:6 (1) 
Arm:61 (13) 
Leg:140 (29) 
Trunk: 265 (56) 
Hand:2 (0.4) 
Foot:2 (0.4) 
 
Clark level of 
invasion: pts (%) 
I: 0 
II: 53(11) 
III: 297 (62) 
IV:114 (24) 
V:1 (0.2) 
Unknown:11 (2)  
 
From Cohn-
Cedermark  
Ulceration n (%) 
Yes:36(18) 
No:153 (78) 
Median: 1.2 
Range: 0.3 – 2.0 
Distribution % 
ns 
 
Location n (%) 
Head – neck:3 (0.4) 
Arm:75 (15) 
Leg:150 (29) 
Trunk:282 (55) 
Hand:1 (0.2) 
Foot:2 (0.4) 
 
Clark level of 
invasion: pts (%) 
I:1 (0.2) 
II: 80 (16) 
III: 304 (59) 
IV: 120 (23) 
V: 0 
Unknown: 8 (2) 
 
From Cohn-
Cedermark  
Ulceration n (%) 
Yes:33 (17) 
No:158 (79) 
Margin of excision 
Median: 2cm 
<2cm: 57pts (12%) 
2cm: 357pts (75%) 
>2cm: 61pts (13%) 
Unknown: 1pt 
(0.2%) 
 
If 2cm had been 
excised at biopsy pt 
did not need to have 
further surgery. 
Numbers not stated.  
Margin of excision 
Median: 5cm 
<5cm: 106pts (21%) 
5cm: 377pts (73%) 
>5cm 27pts (5%) 
Unknown: 3pts 
(1%)  
  
Trial name  Trial details Number in trial Population general characteristics 
 
 
Melanoma characteristics 
 
 
Surgical characteristics 
Margin width 
Deviations  
 Date of trial 
recruitment 
Median follow 
up 
Country 
Narrow 
 
Wide Narrow 
 
Age: median 
(range) 
Gender: m/f % 
Wide 
 
Age: median 
(range) 
Gender: m/f % 
Narrow 
 
Melanoma size (mm) 
Location 
Ulceration: 
Wide 
 
Melanoma size (mm) 
Location 
Ulceration: 
 
Narrow 
 
Margin width (cm) 
Deviations 
Wide 
 
Margin width (cm) 
Deviations 
Not assessed: 8 (4) Not assessed: 9 (5) 
Intergroup 
Melanoma 
Trial  
Intergroup  
[Balch CM 
et al. 2001 8 
Karakousis  
CP et al. 
19967 
Balch CM 
et al. 19936] 
  Inclusion criteria: Clinically localized 
primary melanoma stages I, II.  
Inclusion criteria: 1 to 4mm thick, on trunk, & 
above knee & elbow.  
Planned width: narrow = 2cm, wide = 4cm 
Excision down to the muscular facia.. 
 
1983-1992 
 
Median follow 
up; 10yrs 
n = 244  
 
n = 242 Age:45.3 (19-73) 
Gender:57/43% 
 
Age:47.6 (18-81) 
Gender:57/43% 
 
Median:1.8 
Range: ns 
Distribution n (%) 
1.0 – 1.99: 142(58) 
2.0 – 2.99: 12 (30) 
3.0 – 4.0: 29(12) 
 
Location n (%) 
Limb (Proximal): 90 
(37) 
Trunk: 154 (63) 
 
From Balch 1993 
Ulceration (%) 
Yes: 56 (23) 
No: 188 (77) 
 
 
 
 
 
 
 
 
 
 
 
 
Median: 1.8 
Range: ns 
Distribution  n  (%) 
1.0 – 1.99: 131 (54) 
2.0 – 2.99: 68 (28) 
3.0 – 4.0: 44 (18) 
 
Location n (%) 
Limb (Proximal): 94 
(39) 
Trunk: 148 (61) 
 
From Balch 1993 
Ulceration (%) 
Yes: 56 (23) 
No:  186 (77) 
 
 
 
 
 
 
 
 
 
 
 
 
2cm 4cm 
  
Trial name  Trial details Number in trial Population general characteristics 
 
 
Melanoma characteristics 
 
 
Surgical characteristics 
Margin width 
Deviations  
 Date of trial 
recruitment 
Median follow 
up 
Country 
Narrow 
 
Wide Narrow 
 
Age: median 
(range) 
Gender: m/f % 
Wide 
 
Age: median 
(range) 
Gender: m/f % 
Narrow 
 
Melanoma size (mm) 
Location 
Ulceration: 
Wide 
 
Melanoma size (mm) 
Location 
Ulceration: 
 
Narrow 
 
Margin width (cm) 
Deviations 
Wide 
 
Margin width (cm) 
Deviations 
  
European 
Trial  
French 
 
[Khayat D 
et al. 20039] 
  Inclusion criteria: Primary malignant 
melanoma.  
Inclusion criteria: <2.1cm thick, not on toes, 
nail, or finger. 
Planned width: narrow = 2cm, wide = 5cm 
Excision down to the muscular facia.. 
Surgery within 1mth of excision biopsy.  
Start date 1981  
 
Median follow 
up: 192 mths 
(range 1 to 228 
mths) 
 
Data collection 
complete 2000.  
 
9 European 
centres 
n =161 n = 165 Age: 43 
Gender: 38/62 
 
Age: 45 
Gender: 37/63 
 
Median: 
Range: 
Distribution n (%) 
≤0.5:8 (5) 
0.51-1.0:72 (45) 
1.01-1.5:51 (32) 
≥1.51:30 (18) 
 
Location n (%) 
Head & neck:10 (6) 
  Arm:32 (20) 
  Leg: 55 (34) 
Median: 
Range: 
Distribution n (%) 
≤0.5:10 (6) 
0.51-1.0: 69 (42) 
1.01-1.5: 55 (33) 
≥1.51: 31 (19) 
 
Location n (%) 
Head & neck: 6 (4) 
  Arm:36 (22) 
  Leg: 73(44) 
2cm 
 
 
 
If biopsy excision 
had a 2cm margin 
no further surgery 
required: number 
not given.  
5cm 
  
Trial name  Trial details Number in trial Population general characteristics 
 
 
Melanoma characteristics 
 
 
Surgical characteristics 
Margin width 
Deviations  
 Date of trial 
recruitment 
Median follow 
up 
Country 
Narrow 
 
Wide Narrow 
 
Age: median 
(range) 
Gender: m/f % 
Wide 
 
Age: median 
(range) 
Gender: m/f % 
Narrow 
 
Melanoma size (mm) 
Location 
Ulceration: 
Wide 
 
Melanoma size (mm) 
Location 
Ulceration: 
 
Narrow 
 
Margin width (cm) 
Deviations 
Wide 
 
Margin width (cm) 
Deviations 
Trunk: 47 (29) 
Other: 5 (3) 
Missing: 12 (8) 
 
Clark level of 
invasion n (%) 
I: 8 (5) 
II: 72 (45) 
III: 51 (32) 
IV: 30 (18) 
Trunk: 46 (28) 
Other: 0 
Missing: 4 (2) 
 
 
Clark level of 
invasion n (%) 
I: 10 (6) 
II: 69 (42) 
III: 55 (33) 
IV: 31 (19) 
 
 
 
 
UK Trial  
BAPS/MSG  
 
[Thomas  
  Inclusion criteria: Single primary 
localized cutaneous melanoma.  
Inclusion criteria: 2mm or greater on trunks or 
limbs where a 3cm excision margin was 
possible. (not palms of hands or soles of feet). 
Planned width: narrow = 1cm, wide = 3cm 
  
Trial name  Trial details Number in trial Population general characteristics 
 
 
Melanoma characteristics 
 
 
Surgical characteristics 
Margin width 
Deviations  
 Date of trial 
recruitment 
Median follow 
up 
Country 
Narrow 
 
Wide Narrow 
 
Age: median 
(range) 
Gender: m/f % 
Wide 
 
Age: median 
(range) 
Gender: m/f % 
Narrow 
 
Melanoma size (mm) 
Location 
Ulceration: 
Wide 
 
Melanoma size (mm) 
Location 
Ulceration: 
 
Narrow 
 
Margin width (cm) 
Deviations 
Wide 
 
Margin width (cm) 
Deviations 
JM et al. 
200410] 
 
 
1993-2001 
 
60 mths 
 
UK 
n = 453 n = 447 Age: 57 (16-86) 
Gender: 54/46 
 
Age: 58 (19-92) 
Gender: 49/51 
 
Median: 3.0 
Range: 1.7 – 18.0 
Distribution n (%)  
<2.0: 0.2 
2.0 – 2.5: 160 (35)  
2.6 – 3.0: 83 (18) 
3.1 – 4.0: 91 (21) 
>4.0: 116 (26)  
 
Location (%) 
Limb: 248 (55) 
  Distal: 139 (31) 
  Proximal: 109 (24) 
Trunk: 205 (45) 
 
Ulceration n (%) 
Yes: 63.4% 
No : 36.6% 
Not assessed: 59 (13) 
 
 
Median: 3.1 
Range: 1.0 – 17.0 
Distribution n (%) 
<2.0: 0.4 
2.0 – 2.5: 145 (32.5) 
2.6 – 3.0: 76 (17) 
3.1 – 4.0: 99 (22.2) 
>4.0: 127 (28.3) 
 
Location (%) 
Limb: 239 (54) 
  Distal: 142 (32) 
  Proximal: 97 (22) 
Trunk: 208 (46) 
 
Ulceration n (%) 
Yes: 60.2% 
No: 157 (35)39.8% 
Not assessed: 58 (13) 
 
 
 
 
 
 
1cm 
 
 
 
 
If 1mm initial 
margin then 1cm 
excision: 82.1% 
 
If 1cm initial 
margin then no 
further tx: 17.9% 
3cm 
 
 
 
 
If 1mm initial 
margin then 3cm 
excision: 82.8% 
 
If 1cm initial 
margin then no 
further tx: 17.2% 
(77pts) 
Swedish II 
 
 
[Gillgren P 
et al. 
201111] 
 
 
  Inclusion criteria:  Inclusion criteria:  Planned width: narrow = 2cm, wide = 4cm 
Excision down to the muscular facia.. 
Surgery within 8 wks of excision biopsy.  
 
 
1992 – 2004. 
Had to stop 
early due to 
recruitment 
n = 465 n = 471 Age:59 (49-68) 
Gender : 62/38 
 
Age:60 (50-68) 
Gender:66/34 
 
Median: 
Range: 
Distribution n (%) 
≤3mm: 250 (50) 
Median: 
Range: 
Distribution n (%) 
≤3mm: 230 (49) 
2 cm 
 
Excision biopsy 
could be either 1-
4cm 
 
46 pts only had one 
excision. (10%) 
  
Trial name  Trial details Number in trial Population general characteristics 
 
 
Melanoma characteristics 
 
 
Surgical characteristics 
Margin width 
Deviations  
 Date of trial 
recruitment 
Median follow 
up 
Country 
Narrow 
 
Wide Narrow 
 
Age: median 
(range) 
Gender: m/f % 
Wide 
 
Age: median 
(range) 
Gender: m/f % 
Narrow 
 
Melanoma size (mm) 
Location 
Ulceration: 
Wide 
 
Melanoma size (mm) 
Location 
Ulceration: 
 
Narrow 
 
Margin width (cm) 
Deviations 
Wide 
 
Margin width (cm) 
Deviations 
problems – trial 
originally 
planned as 
equivalence 
study with 2000 
pts.  
 
Median follow 
up: 6.7 yrs. 
Swedish cohort 
followed to 
2011 giving 
11.8 yrs follow 
up. .  
 
Sweden, 
Denmark, 
Estonia, 
Norway.  
>3mm: 233 (50) 
 
 
Location n (%) 
Neck: 2 (<1) 
Trunk: 273 (59) 
Arm: 69(15) 
Leg:119 (26) 
Sole:2 (<1) 
 
Clark level of 
invasion n (%): 
Ii: 6 (1) 
IIi: 107 (23) 
IV: 294 (63) 
V: 34 (7) 
Data unavailable: 24 
(5) 
 
Ulceration n (%) 
Yes:210 (45) 
No: 194 (42%) 
Not assessed: 61 (13) 
>3mm: 241 (51) 
 
 
Location n (%) 
Neck: 0 
Trunk:292 (62) 
Arm:74 (16) 
Leg:104 (22) 
Sole:1 (<1) 
 
Clark level of 
invasion n: 
II: 9 (2) 
III: 121 (26) 
IV: 282 (60) 
V: 37 (8) 
Data unavailable: 22 
(5) 
 
Ulceration n (%) 
Yes:224 (48) 
No:188 (40) 
Not assessed: 59(12) 
3mm or 2cm. If 2cm 
no further surgery 
required. N = 70 pts 
(15%) 
 
74 protocol 
deviations reported  
 
 
 
 
 
71 protocol 
deviations reported  
 
 
Reference List 
 
 (1)  Veronesi U, Cascinelli N, Adamus J, Balch C, Bandiera D, Barchuk A et al. Thin stage I primary cutaneous malignant melanoma. Comparison of 
excision with margins of 1 or 3 cm. N Engl J Med 1988; 318(18):1159-1162. 
 (2)  Veronesi U, Cascinelli N. Narrow excision (1-cm margin). A safe procedure for thin cutaneous melanoma. Arch Surg 1991; 126(4):438-441. 
  
 (3)  Cascinelli N. Margin of resection in the management of primary melanoma. Semin Surg Oncol 1998; 14(4):272-275. 
 (4)  Ringborg U, Andersson R, Eldh J, Glaumann B, Hafstrom L, Jacobsson S et al. Resection margins of 2 versus 5 cm for cutaneous malignant 
melanoma with a tumor thickness of 0.8 to 2.0 mm: randomized study by the Swedish Melanoma Study Group. Cancer 1996; 77(9):1809-1814. 
 (5)  Cohn-Cedermark G, Rutqvist LE, Andersson R, Breivald M, Ingvar C, Johansson H et al. Long term results of a randomized study by the Swedish 
Melanoma Study Group on 2-cm versus 5-cm resection margins for patients with cutaneous melanoma with a tumor thickness of 0.8-2.0 mm. Cancer 
2000; 89(7):1495-1501. 
 (6)  Balch CM, Urist MM, Karakousis CP, Smith TJ, Temple WJ, Drzewiecki K et al. Efficacy of 2-cm surgical margins for intermediate-thickness 
melanomas (1 to 4 mm). Results of a multi-institutional randomized surgical trial. Ann Surg 1993; 218(3):262-267. 
 (7)  Karakousis CP, Balch CM, Urist MM, Ross MM, Smith TJ, Bartolucci AA. Local recurrence in malignant melanoma: long-term results of the 
multiinstitutional randomized surgical trial. Ann Surg Oncol 1996; 3(5):446-452. 
 (8)  Balch CM, Soong SJ, Smith T, Ross MI, Urist MM, Karakousis CP et al. Long-term results of a prospective surgical trial comparing 2 cm vs. 4 cm 
excision margins for 740 patients with 1-4 mm melanomas. Ann Surg Oncol 2001; 8(2):101-108. 
 (9)  Khayat D, Rixe O, Martin G, Soubrane C, Banzet M, Bazex JA et al. Surgical margins in cutaneous melanoma (2 cm versus 5 cm for lesions 
measuring less than 2.1-mm thick). Cancer 2003; 97(8):1941-1946. 
 (10)  Thomas JM, Newton-Bishop J, A'Hern R, Coombes G, Timmons M, Evans J et al. Excision margins in high-risk malignant melanoma. N Engl J Med 
2004; 350(8):757-766. 
 (11)  Gillgren P, Drzewiecki KT, Niin M, Gullestad HP, Hellborg H, Mansson-Brahme E et al. 2-cm versus 4-cm surgical excision margins for primary 
cutaneous melanoma thicker than 2 mm: a randomised, multicentre trial. Lancet 2011; 378(9803):1635-1642. 
 
  
Professor Keith Wheatley, DPhil 
Ms Jayne S. Wilson, MSc 
Mr Piers Gaunt, MSc 
Cancer Research UK Clinical Trials Unit, Institute of Cancer & Genomic Sciences, College 
of Medical and Dental Sciences, University of Birmingham, Birmingham B15 2TT, United 
Kingdom Dr Jerry R. Marsden, FRCP Skin Oncology Service, Queen Elizabeth Hospital 
Birmingham, Mindelsohn Way, Edgbaston, Birmingham B15 2WB, United Kingdom 
  
Conflicts of interest statement:  
The authors declare that there are no conflicts of interest.  
Keith Wheatley 
Professor of Medical Statistics 
 
Jayne Wilson 
Senior Systematic Reviewer 
 
Piers Gaunt 
Senior Statistician 
 
Jerry Marsden 
Consultant Dermatologist 
 
This work was supported by Cancer Research UK, which provides core funding to the Cancer 
Research UK Clinical Trials Unit, University of Birmingham. 
 
 
